Ensysce Biosciences, Inc. ENSC
Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a pain/anesthesia drug developer. Its lead program, PF614, is in Phase 3 for Severe/chronic pain (abuse-resistant TAAP oxycodone prodrug).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PF614 (TAAP oxycodone prodrug) | Severe pain | small molecule | Phase 3 |
| PF614-MPAR | Severe pain with overdose protection | small molecule | Phase 1 |
| Nafamostat | Chronic pain / opioid-related (Phase 1 completed) | small molecule | Phase 1 |
| Cy Biopharma lead candidate (acquired Aug 2026) | Complex Regional Pain Syndrome Type 1 (orphan drug designation) | unclear | Pre-clinical |
Recent results and decisions
- Oct 16, 2026started Phase 2 trial of CY200 for CRPS Type 1 is planned as a randomized, double-blind, placebo-controlled trial in the United Kingdom, with no participant enrolled as of the filing date.
The Phase 2 trial is planned as a randomized, double-blind, placebo-controlled trial with four groups, each receiving two doses three weeks apart: placebo and placebo; 10 mg and placebo; 25 mg and placebo; and 25 mg and 25 mg. The trial is designed to randomize approximately 130 participants so that
Filing - Aug 5, 2026n/a Ensysce Biosciences completed acquisition of Cy Biopharma on August 5, 2026, issuing 282,122 shares of Series C Preferred Stock to Cy equityholders.
On August 5, 2026, we completed our acquisition of Cy Biopharma, Inc. pursuant to an Agreement and Plan of Merger, dated August 5, 2026, by and among us, PHRMA Merger Sub I, Inc., PHRMA Merger Sub II, LLC and Cy Biopharma.
Filing - Aug 5, 2026n/a Ensysce completed initial closing of PIPE Financing concurrent with Cy Biopharma acquisition, raising approximately $21.5 million in gross proceeds.
At the initial closing of the PIPE Financing on August 5, 2026, Ensysce issued 66,811 shares of Series C Preferred Stock at a purchase price of $321.79 per share, or $0.32179 per share on an as-converted basis, resulting in gross proceeds of approximately $21.5 million.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 pain/anesthesia companies
- Mesoblast Ltd MESO
- Not specified in extract Not specified in extract
- Scilex Holding Co SCLX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.